BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Prostate cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for prostate cancer: 431 (223 sponsors; 62 newly posted in the last 180 days, 14 stopped in the last 180 days; 24 new-entrant sponsors). Momentum score 12.5, rank 54 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 132, Phase 2 140, Phase 3 70, Phase 4 6, N/A 80.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 27 | P3 8, NA 7, P4 1, P2 10, P1 1 | 3 | 3 |
| Janssen Research & Development, LLC | 21 | P1 11, P3 7, P2 3 | 3 | 5 |
| Pfizer PFE | 11 | P3 6, P2 2, P1 1, NA 2 | 1 | 1 |
| Novartis Pharmaceuticals NVS | 31 | P3 4, P2 12, NA 9, P1 5, P4 1 | 4 | 5 |
| Aragon Pharmaceuticals, Inc. | 6 | P1 2, P3 4 | 0 | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 12 | P1 4, P3 3, P2 5 | 1 | 4 |
| Merck Sharp & Dohme LLC MRK | 7 | P3 3, P2 4 | 1 | 0 |
| Norroy Bioscience Co., LTD | 4 | P3 3, P2 1 | 3 | 0 |
| FutureChem | 3 | P3 3 | 1 | 0 |
| Amgen AMGN | 7 | P3 2, P1 5 | 0 | 2 |
| Eli Lilly and Company LLY | 7 | P1 5, P3 2 | 0 | 2 |
| Exelixis EXEL | 6 | P3 2, P1 4 | 1 | 2 |
| Clarity Pharmaceuticals Ltd | 3 | P2 1, P3 2 | 0 | 1 |
| Hinova Pharmaceuticals Inc. | 3 | P3 2, P2 1 | 1 | 0 |
| Curium US LLC | 2 | P3 2 | 0 | 0 |
| Telix Pharmaceuticals (Innovations) Pty Limited TLX | 2 | P3 2 | 0 | 1 |
| Bayer | 16 | P1 2, NA 10, P3 1, P4 2, P2 1 | 2 | 2 |
| GlaxoSmithKline | 4 | P2 2, P1 1, P3 1 | 1 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 4 | P1 1, P2 2, P3 1 | 2 | 1 |
| Candel Therapeutics, Inc. CADL | 3 | P2 2, P3 1 | 0 | 1 |
| Five Eleven Pharma, Inc. | 2 | P3 1, P2 1 | 0 | 0 |
| Lantheus Medical Imaging LNTH | 2 | P3 1, NA 1 | 1 | 0 |
| ORIC Pharmaceuticals ORIC | 2 | P3 1, P1 1 | 1 | 0 |
| ABX advanced biochemical compounds GmbH | 1 | P3 1 | 0 | 1 |
| Astellas (Beijing) Pharmaceutical R&D Co., Ltd. | 1 | P3 1 | 0 | 0 |
Recently stopped trials
- NCT06379217 Novartis Pharmaceuticals - terminated: Sponsor decision and not a consequence of any safety concerns. NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastati
- NCT07285694 Arsenal Biosciences, Inc. - terminated: Sponsor decision AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
- NCT03792841 Amgen - terminated: Sponsor Decision Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
- NCT07406282 Bayer - terminated: The PPS data source provided insufficient level of granularity on baseline characteristics, which did not allow building comparable cohorts A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitor
- NCT03834493 Merck Sharp & Dohme LLC - terminated: The study stopped due to futility Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Cast
- NCT04191096 Merck Sharp & Dohme LLC - terminated: The study stopped due to futility Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo
- NCT04615845 Pharmicell Co., Ltd. - terminated: Difficulties in patient recruitment. A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
- NCT04631601 Amgen - terminated: Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety. Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06008483 QSAM Therapeutics, Inc. - terminated: Change in development program indication A Dose Finding Study to Treat Bone Tumor(s)
- NCT06022757 Evopoint Biosciences Inc. - terminated: Strategic decision by Sponsor. Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed
- NCT05422105 Primo Biotechnology Co., Ltd - suspended: Interim Analysis Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient
- NCT05999968 Eli Lilly and Company - terminated: The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint. Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
- NCT07146113 AstraZeneca - suspended: As a part of planned reassessment for the current period, a decision has been made to prioritize, optimize, and reallocate resources. As a r Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federa
- NCT07570966 Novartis Pharmaceuticals - withdrawn: Business decision Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P1/P2 | AstraZeneca AZN | NCT06267729 Study of AZD0754 in Participants With Metastatic Prostate Cancer | Metastatic Prostate Cancer | recruiting | 60 |
| 2026-11-30 est. | P1/P2 | OncoC4, Inc. | NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | active not recruiting | 148 |
| 2026-12 est. | P1/P2 | Sapience Therapeutics | NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain | active not recruiting | 125 |
| 2026-12 est. | P2 | Zenith Epigenetics | NCT04986423 ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | recruiting | 200 |
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P1/P2 | Bivision Pharmaceuticals, Inc. | NCT06139575 Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | Prostate Cancer | recruiting | 90 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06568094 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | Prostate Cancer | recruiting | 100 |
| 2026-12 est. | P2 | Jina Pharmaceuticals Inc. | NCT06890832 A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | Metastatic Castration-resistant Prostate Cancer, MCRPC | not yet recruiting | 75 |
| 2026-12 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07198633 A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | Advanced Prostate Cancer | recruiting | 212 |
| 2026-12-01 est. | P3 | Janssen Research & Development, LLC | NCT03767244 A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Prostatic Neoplasms | active not recruiting | 2517 |
| 2026-12-03 est. | P2 | Novartis Pharmaceuticals NVS | NCT06991556 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Metastatic Hormone-sensitive Prostate Cancer | active not recruiting | 168 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-23 est. | P2 | Novartis Pharmaceuticals NVS | NCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | Prostatic Neoplasm | active not recruiting | 49 |
| 2026-12-23 est. | P2 | Fusion Pharmaceuticals Inc. HTOO | NCT06402331 FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | active not recruiting | 110 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04691804 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placeb | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | 496 |
| 2026-12-31 est. | P3 | Clarity Pharmaceuticals Ltd | NCT06970847 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Prostate Cancer; Prostate Cancer Patients With Detectable PSA Following Prostatectomy; Prostate Canc | active not recruiting | 220 |
| 2027-01 est. | P3 | Telix Pharmaceuticals (Innovations) Pty Limited TLX | NCT07052214 PSMA PET Combined With MRI for the Detection of PCa | PCA; Prostate Cancer; Prostatic Neoplasm; PSMA PET; Diagnostic Imaging; Elevated PSA; Positron Emiss | active not recruiting | 338 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-30 est. | P2 | Curasight | NCT06474806 Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer | Prostate Cancer | recruiting | 168 |
| 2027-02 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06241846 A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer (mCRPC) | recruiting | 100 |
| 2027-02 est. | P2 | Candel Therapeutics, Inc. CADL | NCT07332000 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma) | recruiting | 45 |
| 2027-02-02 est. | P2 | Cellvax Therapeutics Inc | NCT06636682 FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | Prostate Cancer (Adenocarcinoma); Prostate CA; Prostate Cancers; Prostate Cancer (Post Prostatectomy | recruiting | 100 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | NCT03348670 Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | Prostate Cancer | active not recruiting | 600 |
| 2026-11-17 est. | P2 | Novartis Pharmaceuticals NVS | NCT06894511 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC | Metastatic Castration Resistant Prostate Cancer (mCRPC) | active not recruiting | 7 |
| 2026-11-06 est. | P2 | Novartis Pharmaceuticals NVS | NCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | 23 |
| 2026-11-05 est. | P1/P2 | AstraZeneca AZN | NCT07336446 A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | Prostate Cancer | active not recruiting | 6 |
| 2026-11 est. | P1/P2 | TYK Medicines, Inc | NCT07104643 Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC) | mCRPC | not yet recruiting | 48 |
| 2026-10-31 est. | P1/P2 | Orion Corporation, Orion Pharma ORN | NCT03436485 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | active not recruiting | 204 |
| 2026-10-30 est. | P1/P2 | Antelope Surgical Solutions, Inc | NCT06906471 A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging | active not recruiting | 15 |
| 2026-10-19 | P1/P2 | Arsenal Biosciences, Inc. | NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | 3 |
| 2026-10-12 est. | P3 | Janssen Research & Development, LLC | NCT05884398 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC | Metastatic Castrate-sensitive Prostate Cancer | active not recruiting | 420 |
| 2026-10 est. | P1/P2 | TYK Medicines, Inc | NCT07104617 Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC) | Metastatic Castration-resistant Prostate Cancer (mCRPC) | not yet recruiting | 48 |
| 2026-10 est. | P3 | Curium US LLC | NCT06235151 Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Prostate Cancer; Prostate Adenocarcinoma | active not recruiting | 439 |
| 2026-09 est. | P3 | Clarity Pharmaceuticals Ltd | NCT06056830 Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Prostate Cancer; Prostatic Neoplasms | recruiting | 383 |
| 2026-09 est. | P1/P2 | Clarity Pharmaceuticals Ltd | NCT04868604 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Prostatic Neoplasms, Castration-Resistant | recruiting | 54 |
| 2026-08-27 est. | P1/P2 | Blue Earth Therapeutics Ltd | NCT05413850 Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC; Urogenital Neoplasms; Prost | recruiting | 82 |
| 2026-08 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07056439 Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients | PET Imaging in Patients With Prostate Cancer | not yet recruiting | 50 |
| 2026-08 est. | P1/P2 | AtlasMedx, Incorporated | NCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Advanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Pro | recruiting | 122 |
| 2026-06-24 | P2 | Debiopharm International SA | NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Prostate Cancer | completed | 55 |
| 2026-06-11 | P3 | HTA Co., Ltd. | NCT06754085 Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | Prostate Cancer | completed | 131 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "prostate cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.